Trials / Recruiting
RecruitingNCT07298343
Evaluating the Efficacy and Tolerability of ZED1227 in Subjects With Non-responsive Celiac Disease
A Phase II, Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy and Tolerability of ZED1227 in Celiac Disease Subjects Experiencing Symptoms Despite Gluten-free Diet
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 356 (estimated)
- Sponsor
- Dr. Falk Pharma GmbH · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A study to discover if ZED1227 can improve continued celiac disease symptoms despite a gluten-free diet
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZED1227 + SIGE | oral treatment with different daily doses of ZED1227 vs placebo |
| OTHER | Placebo | Placebo + SIGE |
Timeline
- Start date
- 2024-06-10
- Primary completion
- 2027-08-01
- Completion
- 2027-08-01
- First posted
- 2025-12-23
- Last updated
- 2026-04-02
Locations
1 site across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07298343. Inclusion in this directory is not an endorsement.